GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alivus Life Sciences Ltd (NSE:ALIVUS) » Definitions » Research & Development

Alivus Life Sciences (NSE:ALIVUS) Research & Development : ₹0 Mil (TTM As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Alivus Life Sciences Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Alivus Life Sciences's Research & Development for the three months ended in Dec. 2024 was ₹0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 was ₹0 Mil.

Alivus Life Sciences Research & Development Historical Data

The historical data trend for Alivus Life Sciences's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alivus Life Sciences Research & Development Chart

Alivus Life Sciences Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Research & Development
Get a 7-Day Free Trial - 2.90 - - -

Alivus Life Sciences Quarterly Data
Mar19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Alivus Life Sciences Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alivus Life Sciences  (NSE:ALIVUS) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Alivus Life Sciences Research & Development Related Terms

Thank you for viewing the detailed overview of Alivus Life Sciences's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Alivus Life Sciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alivus Life Sciences Ltd (NSE:ALIVUS) » Definitions » Research & Development
Comparable Companies
BOM:530019 BOM:524816 BOM:532482 BOM:524742 BOM:524558 BOM:500126 BOM:533573 BOM:544222 BOM:540596 BOM:543748 ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD XSWX:SDZ HKSE:03692 NSE:DIVISLAB XTAE:TEVA
Traded in Other Exchanges
543322:India
Address
470, Cardinal Gracious Road, 4th Floor, OIA House, Andheri (East), Mumbai, MH, IND, 400 099
Website
https://www.alivus.com
Alivus Life Sciences Ltd, formerly Glenmark Life Sciences Ltd develops, manufactures, and supplies high-quality active pharmaceutical ingredients for cardiovascular disease, central nervous system disease, pain management, diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas.

Alivus Life Sciences Headlines

No Headlines